XOLREMDI Capsule Ref.[109813] Active ingredients: Mavorixafor

Source: FDA, National Drug Code (US)  Revision Year: 2024 

1. Indications and Usage

XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

2. Dosage and Administration

2.1 Recommended Dosage

The recommended dosage of XOLREMDI is:

  • Weight more than 50 kg: 400 mg orally once daily on an empty stomach after an overnight fast, and at least 30 minutes before food.
  • Weight less than or equal to 50 kg: 300 mg orally once daily on an empty stomach after an overnight fast, and at least 30 minutes before food.

Swallow the capsules whole. Do not open, break, or chew capsules.

If a dose of XOLREMDI is missed, the next dose should be taken as scheduled. Do not take more than one XOLREMDI dose each day.

2.2 Dosage Modifications for Strong CYP3A4 Inhibitors

Reduce daily dosage of XOLREMDI to 200 mg when used concomitantly with strong CYP3A4 inhibitors [see Drug Interactions (7.1)].

16.2. Storage and Handling

Store XOLREMDI refrigerated at 2°C to 8°C (36°F to 46°F). Keep bottle tightly closed. Store in and dispense from original container to protect from moisture.

< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈